Table S2: Identification Marker Candidates

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Protein** | **Other names** | **Reported on GBM Cells** | **Reported on Blood Cells** | **Antibody, type, [clone], dilution IC** | **Detected in this study** |
| **GFAP** | N/A | Yes(1-3) | No(3) | αGFAP\*; IgG; [polyclonal]; 1:100 | Not in GBM cell lines or PBMCs |
| **GLAST** | EAAT1; GluT-1; SLC1A3 | Yes(4 ) | No(3) | αGLAST#; IgG; [polyclonal]; 1:100 | In all GBM cell lines, negligible on PBMC |
| **Nestin** | N/A | Yes(5, 6) | Yes(7) | α-nestin\*; IgG; [polyclonal]; 1:1000 | In GBMs but also PBMCs |
| **OLIG2** | RACK17 | Yes(8) | No(9) | αOLIG2+; IgG; [polyclonal]; 1:250 | Not in GBM cell lines |
| **Her2** | ErbB2 | Yes (10) | low(11) | αHer2§; IgG1; [24D2]; 1:200 | Not or weak on GBM cells |
| **Her3** | ErbB3 | Yes(12) | LPS inducible (13) | αHer3\*; IgG1; [H3.105.5]; 1:100 | Not on GBM cells |

\*Merck, St. Louis, USA (AB5804; AB5922); # Novus Biologicals (NB100-1869F); +Sigma-Aldrich, St. Louis, USA (AV31464); §Miltenyi Biotec, Bergisch Gladbach, Germany;

IC: immunocytostaining

**References**

1. Hara A, Sakai N, Yamada H, Niikawa S, Ohno T, Tanaka T, et al. Proliferative assessment of GFAP-positive and GFAP-negative glioma cells by nucleolar organizer region staining. Surgical neurology. 1991;36(3):190-4.

2. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Science translational medicine. 2014;6(247):247ra101-247ra101.

3. Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Blal HA, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.

4. Ye Z-C, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction–mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine–glutamate exchange. The Journal of Neuroscience. 1999;19(24):10767-77.

5. Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L, et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res. 2007;13(23):6970-7.

6. MacArthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer research. 2014;74(8):2152-9.

7. Reimer R, Helmbold H, Szalay B, Hagel C, Hohenberg H, Deppert W, et al. Nestin modulates glucocorticoid receptor function by cytoplasmic anchoring. PLoS One. 2009;4(6):e6084.

8. Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004;63(5):499-509.

9. Hwang SM, Uhm TG, Lee SK, Kong SK, Jung KH, Binas B, et al. Olig2 is expressed late in human eosinophil development and controls Siglec-8 expression. J Leukoc Biol. 2016;100(4):711-23.

10. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64(14):4980-6.

11. You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol. 2008;1:2.

12. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, et al. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia. 2012;14(5):420-8.

13. Wang H, Jin Y, Reddy MV, Podolsky R, Liu S, Yang P, et al. Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk. PLoS One. 2010;5(7):e11789.